Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462305 · ClinicalTrials.gov registry record · NA
30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
A NA study of Seasonal Affective Disorder, sponsored by Philips Respironics.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT01462305: Completed NA study of Seasonal Affective Disorder, sponsored by Philips Respironics.
NCT01462305 is a NA study of Seasonal Affective Disorder that has completed, run by Philips Respironics. The registered enrollment target is 35 participants, below the 72-participant average among 3 other Seasonal Affective Disorder trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01462305, a NA study of Seasonal Affective Disorder, has completed, sponsored by Philips Respironics.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD). It is hypothesized that the 467nm light will improve the symptoms of SAD better than the 580nm light.
Primary Outcome
A Structured Interview Guide for the Hamilton Depression Scale with Atypical Depression Supplement was utilized at baseline and after 6 weeks of treatment. The SIGH-ADS is designed for general use in depression research and clinical evaluation, regardless of seasonality.The SIGH-ADS rates the severity of depressive symptoms in terms of Hamilton's 17-item depression score and an 8-item atypical score. Combined this provides 25 items to provide the SIGH-ADS score. SIGH-ADS scores range from 0-79;
Conditions Studied
Interventions
- DEVICE Control
- DEVICE goLITE
Study Locations (4)
Massachusetts
- McLean Hospital - Belmont
- Brigham & Women's Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Community Research Management Associates - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-01-06 |
| Est. Completion | 2012-04-02 |
| Phase | NA |
What the finished NCT01462305 record still lists
NCT01462305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 72-participant average among 3 other Seasonal Affective Disorder trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Seasonal Affective Disorder appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT01462305 reports a single indexed study location in Massachusetts, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT01462305 about?
NCT01462305 is a clinical study titled "30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder". The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD). It is hypothesized that the 467nm light will improve the symptoms of SAD better than the 580nm light.
What is the current status of trial NCT01462305?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2012-01-06. Estimated completion is 2012-04-02.
What conditions does trial NCT01462305 study?
This clinical trial studies the following conditions: Seasonal Affective Disorder.
What interventions are being tested in trial NCT01462305?
The interventions under investigation include: Control (DEVICE), goLITE (DEVICE).
Who is sponsoring clinical trial NCT01462305?
This trial is sponsored by Philips Respironics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01462305 being conducted?
This trial has 4 study locations across Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Affective Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Season on Melatonin Secretion in Healthy Men and Women and Patients With Seasonal Affective Disorder
COMPLETED
-
Study of Genes in Relation to Seasonal Affective Disorder and Major Depressive Disorder
COMPLETED
-
Clinical Trial of Propranolol for Seasonal Affective Disorder
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI